SubHero Banner
Text

Ofev® (nintedanib) – Expanded indication

March 9, 2020 - The FDA announced the approval of Boehringer Ingelheim’s Ofev (nintedanib), for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.

Download PDF